Therapeutic angiogenesis: The pros and cons and the future

Korean Circulation Journal

Volumn 38, Issue 2, 2008, Pages 73-79

  Jae, Kean Ryu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Angiogenesis; Cell therapy; Clinical trial; Neovascularization

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ACUTE HEART INFARCTION; ANGIOGENESIS; CELL THERAPY; CLAUDICATION; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MONITORING; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POPULATION; REVIEW; SAFETY; STABLE ANGINA PECTORIS;

EID: 41349099417     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.2.73     Document Type: Review

References (46)

1. Kim HJ, Kim DK. Angiogenic gene therapy in patients with ischemic cardiovascular diseases. Korean Circ J 2003;33:7-14.
2. Choi JH, Kim DK. Therapeutic angiogenesis for cardiovascular diseases: the present and future. Korean Circ J 2003;33:739-45.
3. Simons M. Angiogenesis: where do we stand now? Circulation 2005;111:1556-66.
4. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation 2000;102:e73-86.
5. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:208-16.
6. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
7. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
8. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 2000;190:338-42.
9. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-9.
10. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004;94:230-8.
11. Vartanian SM, Sarkar R. Therapeutic angiogenesis. Vasc Endovascular Surg 2007;41:173-85.
12. Yanagisawa MA, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
13. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994;90:II228-34.
14. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
15. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65.
16. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
17. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42:1339-47.
18. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study. J Am Coll Cardiol 2005;45:982-8.
19. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascidar endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8.
20. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial Hum Gene Ther 2006;17;683-91.
21. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
22. Scholz D, Ziegelhoeffer T, Helisch A, et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 2002;34:775-87.
23. Lee CW, Stabile E, Kinnaird T, et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Am Coll Cardiol 2004;43:474-82.
24. Post MJ, Simons M. Gene therapy versus protein-based therapy: a matter of pharmacokinetics. Drug Discov Today 2001;6:769-70.
25. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
26. Lu E, Wagner WR, Schellenberger U, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003;108:97-103.
27. Pearlman JD, Laham RJ, Post M, Leiner T, Simons M. Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Des 2002;8:1467-96.
28. Viswamitra S, Higgins CB, Meacham DF, Mehta JL. Magnetic-resonance imaging in myocardial ischemia. Curr Opin Cardiol 2004;19:510-6.
29. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reduc tase inhibition. Arterioscler Thromb Vasc Biol 2002;22:1567-72.
30. Sata M. Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. Trends Cardiovasc Med 2003;13:249-53.
31. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003;108:2710-5.
32. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93:e17-24.
33. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
34. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004;363:751-6.
35. Yla-Hurttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth Nat Med 2003;9:694-701.
36. Corti R, Badimon J, Mizsei G, et al. Real time magnetic resonance guided endomyocardial local delivery. Heart 2005;91:348-53.
37. Yoon CH, Seo JB, Hur J, et al. Characterization of two types of endothelial progenitor cells (EPC). Korean Circ J 2004;34:304-13.
38. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53.
39. Cheon IS, Choi JH, Kim KL, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Korean Circ J 2004;34:1033-42.
40. Joe YA, Baek SH, Park HE, et al. In vitro differentiation of endothelial precursor cells derived form umbilical cord blood. Korean Circ J 2002;32:646-54.
41. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002;106:3009-17.
42. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-5.
43. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-8.
44. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367:113-21.
45. Lunde K, Solheim S, Aakhus S, et al. Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial: intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J 2005;39:150-8.
46. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21.